Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3912]

Lower levels of inflammatory markers and tumour burden is linked to...

Prof Bertrand Arnulf - Hôpital Saint-Louis, Paris, France

Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide-Cel in R/R multiple myeloma ( Prof Bertrand Arnulf - Hôpital Saint-Louis, Paris, France )

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL...

Dr Alessandra Tedeschi - Niguarda Cancer Center, Milan, Italy

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) and/or TP53 mutation ( Dr Alessandra Tedeschi - Niguarda Cancer Center, Milan, Italy )

Isatuximab in combination with pomalidomide and dexamethasone shows promising...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157...

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )

PD-1–refractory advanced melanoma: how do we get to the finish line?

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

$PD-1–refractory advanced melanoma: how do we get to the finish line? ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )$

Highlights in melanoma from ASCO 2024

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

Highlights in melanoma from ASCO 2024 ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )

Encouraging results using mismatched unrelated donors in stem cell...

Dr Monzr Al Malki and Dr Steven Devine

Encouraging results using mismatched unrelated donors in stem cell transplantation ( Dr Monzr Al Malki and Dr Steven Devine )

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients...

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

Quality of life and patient satisfaction of Filipinos after breast conservation...

Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines

Quality of life and patient satisfaction of Filipinos after breast conservation surgery and intraoperative radiotherapy ( Dr Angeli Andrea Cocos-Alcantara - The Medical City, Pasig, Philippines )

Importance of MRD in newly developed multiple myeloma

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

Importance of MRD in newly developed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel...

Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Martin Schostak, Dr Alexander Wyatt, Prof Charles Ryan and Dr Emmanuel Antonarakis )

Cancer advocacy and fundraising in Nigeria

Dr Zainab Shinkafi-Bagudu - Founder, Medicaid Cancer Foundation

Cancer advocacy and fundraising in Nigeria ( Dr Zainab Shinkafi-Bagudu - Founder, Medicaid Cancer Foundation )

More from ecancer